Antibiotics in Oncology

Cancer patients develop neutropenia, a decrease in the subset of leucocytes responsible for protection against bacteria, as a result of chemotherapy or cancer. Neutropenia predisposes the patients to severe bacterial infections. Standard antibiotic regimens for cancer patients with neutropenia and fever are directed at most of the bacteria that can cause infections. However, a subset of resistant bacteria belonging to the gram-positive group (Staphylococcus aureus and Streptococci) remain untreated unless specific antibiotics are added to the treatment. For patients receiving chemotherapy, there is an increased risk of infection due to a low white blood cell count (neutropenia) caused by a toxic effect of chemotherapy on the bone marrow. Antibiotic prophylaxis significantly decreased the risk of death when compared to no intervention. Antibiotic prophylaxis also decreased the risk of death from infection and the risk of development of fever.

    Related Conference of Antibiotics in Oncology

    July 01-02, 2019

    11th International Virology Summit

    Valencia, spain
    July 26-27, 2019

    World Yeast Congress

    Vancouver | Canada
    August 19-20, 2019 ,

    14th International Conference on Microbial Interactions & Microbial Ecology

    Mercure Hotel Wien Westbahnhof ,Vienna, Austria
    October 21-22, 2019

    6th World Congress and Expo on Applied Microbiology

    Rome, Italy
    October 23-24, 2019

    2nd Global Experts Meeting on Chronic Diseases

    Tokyo, Japan
    November 06-07, 2019 |

    15th Global Summit on Virology and Microbiology

    Yokohama | Japan
    November 14-15, 2019

    23rd World Congress on Biotechnology

    Amsterdam, Netherlands
    December 04-05, 2019

    Orthodontics and Prosthodontics

    Tokyo, Japan

    Antibiotics in Oncology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in